BioSpectrum
the business of Bio & Health Sciences

DiaCarta receives ICMR approval for QuantiVirus SARS-CoV-2 test

21 July 2020 | News

The evaluation showed 100% sensitivity and 100% specificity



US based company DiaCarta, a precision molecular diagnostics company with a unique, patented XNA technology platform for the development of novel liquid biopsy tests, has announced that its QuantiVirus™ SARS-CoV-2 RT-PCR test kit has been successfully evaluated by the Indian Council of Medical Research (ICMR).

The evaluation showed 100% sensitivity and 100% specificity without any interference with other respiratory viruses and has been cleared for sale in the Indian market.

“With an urgent global need for the availability of highly sensitive and specific tests to minimize the risk of false-negative results and mitigate the ongoing transmission of the deadly virus, we are pleased that our test has met the stringent requirements of the regulatory agencies in Mexico and India and has received regulatory approvals,” said Dr. Ramanathan Vairavan, Senior Vice President at DiaCarta. He further said that “with increasing incidence of COVID-19 around the globe, there is a need for cost efficient tests that are easy to perform on commonly available qPCR platforms. At DiaCarta, we are committed to work with governmental and private institutions to increase test availability and arrest the spread of the coronavirus. In addition, the DiaCarta CLIA certified laboratory in the San Francisco Bay Area has been actively engaged to provide COVID-19 testing to support America’s *Back to Work* and *Back to School* initiatives.”